The estimated Net Worth of Robert Joseph Jr Toth is at least $98.8 Thousand dollars as of 18 March 2014. Mr. Toth owns over 25,000 units of DelMar Pharmaceuticals stock worth over $58,290 and over the last 11 years he sold DMPI stock worth over $0. In addition, he makes $40,500 as Independent Director at DelMar Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Toth DMPI stock SEC Form 4 insiders trading
Robert has made over 4 trades of the DelMar Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of DMPI stock worth $32,500 on 18 March 2014.
The largest trade he's ever made was buying 25,000 units of DelMar Pharmaceuticals stock on 18 March 2014 worth over $32,500. On average, Robert trades about 1,673 units every 2 days since 2014. As of 18 March 2014 he still owns at least 43,500 units of DelMar Pharmaceuticals stock.
You can see the complete history of Mr. Toth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Toth biography
Robert J. Toth Jr. serves as Independent Director of the Company. Mr. Toth has primarily been managing his personal investment portfolio. From 2004-2005, Mr. Toth served as a consulting analyst to Narragansett Asset Management, a New York-based healthcare-focused hedge fund, where he advised the firm on biotechnology investments. From 2001-2003, he was the Senior Portfolio Manager for San Francisco-based EGM Capital’s Medical Technology hedge fund, where he was responsible for managing and maintaining a dedicated medical technology portfolio. Mr. Toth began his Wall Street career in 1996 as an Equity Research Associate for Vector Securities International, a healthcare-focused brokerage firm. From 1997-1999 he served as Senior Biotechnology Analyst. He joined Prudential Securities as Senior Vice President and Biotechnology Analyst where he served from 1999-2001 following Prudential’s acquisition of Vector. His responsibilities included the analysis of commercial, clinical and scientific fundamentals of oncology and genomics-based biotechnology companies on behalf of institutional investors. Mr. Toth was named to the Wall Street Journal’s Allstar List for stock picking in 1999. Mr. Toth received an MBA from the University of Washington and Bachelor of Science degrees in Biological Sciences and Biochemistry from California Polytechnic State University, San Luis Obispo. Mr. Toth’s financial and biotechnology industry knowledge and experience quality him to serve on our Board of Directors.
What is the salary of Robert Toth?
As the Independent Director of DelMar Pharmaceuticals, the total compensation of Robert Toth at DelMar Pharmaceuticals is $40,500. There are 4 executives at DelMar Pharmaceuticals getting paid more, with Saiid Zarrabian having the highest compensation of $939,035.
How old is Robert Toth?
Robert Toth is 57, he's been the Independent Director of DelMar Pharmaceuticals since 2013. There are 2 older and 4 younger executives at DelMar Pharmaceuticals. The oldest executive at DelMar Pharmaceuticals, Inc. is Dennis Brown, 71, who is the Chief Scientific Officer.
What's Robert Toth's mailing address?
Robert's mailing address filed with the SEC is 12707 HIGH BLUFF DR. SUITE 200, , SAN DIEGO, CA, 92130.
Insiders trading at DelMar Pharmaceuticals
Over the last 11 years, insiders at DelMar Pharmaceuticals have traded over $104,000 worth of DelMar Pharmaceuticals stock and bought 663,835 units worth $651,854 . The most active insiders traders include John K Bell, Robert Hoffman, and Jeffrey Bacha. On average, DelMar Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $20,766. The most recent stock trade was executed by John K Bell on 13 September 2019, trading 35,000 units of DMPI stock currently worth $23,800.
What does DelMar Pharmaceuticals do?
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
What does DelMar Pharmaceuticals's logo look like?
Complete history of Mr. Toth stock trades at DelMar Pharmaceuticals
DelMar Pharmaceuticals executives and stock owners
DelMar Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Saiid Zarrabian,
President, Chief Executive Officer, Director -
Scott Praill,
Chief Financial Officer -
Dennis Brown,
Chief Scientific Officer -
Robert Hoffman,
Independent Chairman of the Board -
Robert Toth,
Independent Director -
Keith Murphy,
Director -
John Liatos,
Director -
Erich Mohr,
Director -
Napoleone Ferrara,
Director -
John K Bell,
Director -
Lynda Sarah Cranston,
Director -
William J Garner,
Director -
Jeffrey Bacha,
Chief Executive Officer